Skip to main content
Top
Gepubliceerd in: Huisarts en wetenschap 5/2016

01-05-2016 | Nascholing

Een invaliderende ontstekingsziekte van de huid

Auteurs: Ouliana Kouznetsova, dr. Hessel van der Zee, dr. Wim van der Meijden

Gepubliceerd in: Huisarts en wetenschap | Uitgave 5/2016

Log in om toegang te krijgen
share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail

Samenvatting

Kouznetsova OI, Van der Zee HH, Van der Meijden WI. Een invaliderende ontstekingsziekte van de huid. Huisarts Wet 2016;59(5):212-6.
Hidradenitis suppurativa (HS) is een chronische, invaliderende ontstekingsziekte van de huid. HS wordt gekenmerkt door pijnlijke, ontstoken nodi, abcessen, fistels en fibrosering van de huid met hypertrofische littekens. HS manifesteert zich doorgaans in het tweede en derde decennium van het leven. Het betreft primair een aandoening van de haarfollikels, waarbij immuundysregulatie een rol speelt. Het is geen infectieziekte en heeft een andere pathogenese dan acne. Bekende risicofactoren zijn roken, overgewicht en een positieve familieanamnese. HS heeft, vergeleken met veel andere chronische dermatologische ziekten, een significante impact op de kwaliteit van leven. De behandeling bestaat uit lokale, systemische en/of chirurgische therapie, afhankelijk van de ernst en uitbreiding van de ziekte. Door ontstekingsremmende biologics en chirurgisch ingrijpen te combineren valt vaak een remissie te bereiken. Wanneer huisartsen HS vroeg herkennen, kunnen ze tijdig een adequate behandeling inzetten waarmee ze uitbreiding van de ziekte en het ontstaan van complicaties kunnen beperken. Huisartsen kunnen zelf milde HS-verschijnselen behandelen. Bij onvoldoende verbetering of bij ernstige ziekte moet de patiënt een verwijzing naar de dermatoloog krijgen. Huisartsen spelen ook een rol bij het bestrijden van risicofactoren en met betrekking tot de psychosociale gevolgen van de ziekte.
Literatuur
1.
go back to reference Sillevis Smitt JH, Van Everdingen JJE, Starink TM, De Haan M. Dermatovenereologie voor de eerste lijn. Houten: Bohn Stafleu van Loghum, 2004. Sillevis Smitt JH, Van Everdingen JJE, Starink TM, De Haan M. Dermatovenereologie voor de eerste lijn. Houten: Bohn Stafleu van Loghum, 2004.
3.
go back to reference Wollina U, Koch A, Heinig B, Kittner T, Nowak A. Acne inversa (hidradenitis suppurativa): a review with a focus on pathogenesis and treatment. Indian Dermatol Online J 2013;4:2-11.CrossRef Wollina U, Koch A, Heinig B, Kittner T, Nowak A. Acne inversa (hidradenitis suppurativa): a review with a focus on pathogenesis and treatment. Indian Dermatol Online J 2013;4:2-11.CrossRef
4.
go back to reference Von Laffert M, Helmbold P, Wohlrab J, Fiedler E, Stadie V, Marsch W. Hidradenitis suppurativa (acne inversa): early inflammatory events at terminal follicles and at interfollicular epidermis. Exp Dermatol 2010;19:533-7.CrossRef Von Laffert M, Helmbold P, Wohlrab J, Fiedler E, Stadie V, Marsch W. Hidradenitis suppurativa (acne inversa): early inflammatory events at terminal follicles and at interfollicular epidermis. Exp Dermatol 2010;19:533-7.CrossRef
5.
go back to reference Jemec GB, Revuz J, Leyden JJ. Hidradenitis Suppurativa. Berlijn: Springer-Verlag, 2006.CrossRef Jemec GB, Revuz J, Leyden JJ. Hidradenitis Suppurativa. Berlijn: Springer-Verlag, 2006.CrossRef
6.
go back to reference Jemec GB, Heidenheim M, Nielsen NH. The prevalence of hidradenitis suppurativa and its potential precursor lesions. J Am Acad Dermatol 1996;35:191-4.CrossRefPubMed Jemec GB, Heidenheim M, Nielsen NH. The prevalence of hidradenitis suppurativa and its potential precursor lesions. J Am Acad Dermatol 1996;35:191-4.CrossRefPubMed
7.
go back to reference Canoui-Poitrine F, Revuz JE, Wolkenstein P, Viallette C, Gabison G, Pouget F, et al. Clinical characteristics of a series of 302 French patients with hidradenitis suppurativa, with an analysis of factors associated with disease severity. J Am Acad Dermatol 2009;61:51.CrossRefPubMed Canoui-Poitrine F, Revuz JE, Wolkenstein P, Viallette C, Gabison G, Pouget F, et al. Clinical characteristics of a series of 302 French patients with hidradenitis suppurativa, with an analysis of factors associated with disease severity. J Am Acad Dermatol 2009;61:51.CrossRefPubMed
8.
go back to reference Berna-Serna JD, Berna-Mestre JD. Follicular occlusion due to hyperkeratosis: a new hypothesis on the pathogenesis of mammillary fistula. Med Hypotheses 2010;75:553-4.CrossRefPubMed Berna-Serna JD, Berna-Mestre JD. Follicular occlusion due to hyperkeratosis: a new hypothesis on the pathogenesis of mammillary fistula. Med Hypotheses 2010;75:553-4.CrossRefPubMed
9.
go back to reference Von Laffert M, Stadie V, Wohlrab J, Marsch WC. Hidradenitis suppurativa/acne inversa: bilocated epithelial hyperplasia with very different sequelae. Br J Dermatol 2011;164:367.CrossRef Von Laffert M, Stadie V, Wohlrab J, Marsch WC. Hidradenitis suppurativa/acne inversa: bilocated epithelial hyperplasia with very different sequelae. Br J Dermatol 2011;164:367.CrossRef
10.
go back to reference Konig A, Lehmann C, Rompel R, Happle R. Cigarette smoking as a triggering factor of hidradenitis suppurativa. Dermatology 1999;198:261-4.CrossRefPubMed Konig A, Lehmann C, Rompel R, Happle R. Cigarette smoking as a triggering factor of hidradenitis suppurativa. Dermatology 1999;198:261-4.CrossRefPubMed
11.
go back to reference Rompel R, Petres J. Long-term results of wide surgical excision in 106 patients with hidradenitis suppurativa. Dermatol Surg 2000;26:638-43.CrossRefPubMed Rompel R, Petres J. Long-term results of wide surgical excision in 106 patients with hidradenitis suppurativa. Dermatol Surg 2000;26:638-43.CrossRefPubMed
12.
go back to reference Yazdanyar S, Jemec G. Hidradenitis suppurativa: a review of cause and treatment. Curr Opin Infect Dis 2010;24:118-23.CrossRef Yazdanyar S, Jemec G. Hidradenitis suppurativa: a review of cause and treatment. Curr Opin Infect Dis 2010;24:118-23.CrossRef
13.
go back to reference Van der Zee HH, Van der Woude CJ, Florencia EF, Prens EP. Hidradenitis suppurativa and inflammatory bowel disease: are they associated? Results of a pilot study. Brit J Dermatol 2009;162:195-7. Van der Zee HH, Van der Woude CJ, Florencia EF, Prens EP. Hidradenitis suppurativa and inflammatory bowel disease: are they associated? Results of a pilot study. Brit J Dermatol 2009;162:195-7.
14.
15.
go back to reference Morgan WP, Leicester G. The role of depilation and deodorants in hidradenitis suppurativa. Arch Dermatol 1982;118:101-2.CrossRefPubMed Morgan WP, Leicester G. The role of depilation and deodorants in hidradenitis suppurativa. Arch Dermatol 1982;118:101-2.CrossRefPubMed
16.
go back to reference Poli F, Jemec GB, Revuz J. Clinical presentation. In: Jemec GB. Hidradenitis Suppurativa. Berlin: Springer-Verlag; 2006:11-24.CrossRef Poli F, Jemec GB, Revuz J. Clinical presentation. In: Jemec GB. Hidradenitis Suppurativa. Berlin: Springer-Verlag; 2006:11-24.CrossRef
17.
go back to reference Von der Werth JM, Williams HC. The natural history of hidradenitis suppurativa. J Eur Acad Dermatol Venereol 2000;14:389-92.CrossRefPubMed Von der Werth JM, Williams HC. The natural history of hidradenitis suppurativa. J Eur Acad Dermatol Venereol 2000;14:389-92.CrossRefPubMed
18.
go back to reference Onderdijk AJ, Van der Zee HH, Esmann S, Lophaven S, Dufour DN, Jemec GB, et al. Depression in patients with hidradenitis suppurativa. J Eur Acad Dermatol Venereol 2013;27:473-8.CrossRefPubMed Onderdijk AJ, Van der Zee HH, Esmann S, Lophaven S, Dufour DN, Jemec GB, et al. Depression in patients with hidradenitis suppurativa. J Eur Acad Dermatol Venereol 2013;27:473-8.CrossRefPubMed
19.
go back to reference Wolkenstein P, Loundou A, Barrau K, Auquier P, Revuz J, Quality of Life Group of the French Society of Dermatology. Quality of life impairment in hidradenitis suppurativa: a study of 61 cases. J Am Acad Dermatol 2007;56:621.CrossRefPubMed Wolkenstein P, Loundou A, Barrau K, Auquier P, Revuz J, Quality of Life Group of the French Society of Dermatology. Quality of life impairment in hidradenitis suppurativa: a study of 61 cases. J Am Acad Dermatol 2007;56:621.CrossRefPubMed
20.
go back to reference Hurley HJ. Axillary hyperhidrosis, apocrine bromhidrosis, hidradenitis suppurativa and familial benign pemphigus surgical approach. In: Roenigk RK, Roenigk HH. Dermatologic Surgery. New York: Marcel Dekker, 1989:729-39. Hurley HJ. Axillary hyperhidrosis, apocrine bromhidrosis, hidradenitis suppurativa and familial benign pemphigus surgical approach. In: Roenigk RK, Roenigk HH. Dermatologic Surgery. New York: Marcel Dekker, 1989:729-39.
21.
go back to reference Zouboulis CC, Desai N, Emtestam L, Hunger RE, Ioannides D, Juhász I, et al. European S1 guideline for the treatment of hidradenitis suppurativa/acne inversa. J Eur Acad Dermatol Venereol 2015;29:619-44.CrossRefPubMed Zouboulis CC, Desai N, Emtestam L, Hunger RE, Ioannides D, Juhász I, et al. European S1 guideline for the treatment of hidradenitis suppurativa/acne inversa. J Eur Acad Dermatol Venereol 2015;29:619-44.CrossRefPubMed
23.
go back to reference Saunte DM, Boer J, Stratigos A, Szepietowski JC, Hamzavi I, Kim KH, et al. Diagnostic delay in hidradenitis suppurativa is a global problem. Brit J Dermatol Epub 2015 Nov 3. doi:10.1111/bjd.14038. Saunte DM, Boer J, Stratigos A, Szepietowski JC, Hamzavi I, Kim KH, et al. Diagnostic delay in hidradenitis suppurativa is a global problem. Brit J Dermatol Epub 2015 Nov 3. doi:10.1111/bjd.14038.
24.
go back to reference Alikhan A, Lynch PJ, Eisen DB. Hidradenitis suppurativa: a comprehensive review. J Am Acad Dermatol 2009;60:539.CrossRefPubMed Alikhan A, Lynch PJ, Eisen DB. Hidradenitis suppurativa: a comprehensive review. J Am Acad Dermatol 2009;60:539.CrossRefPubMed
25.
go back to reference Faye O, Petit F, Poli F, et al. Lymphedema as a complication of hidradenitis suppurativa in three patients. Ann Dermatol Venereol 2007;134:567-9.CrossRefPubMed Faye O, Petit F, Poli F, et al. Lymphedema as a complication of hidradenitis suppurativa in three patients. Ann Dermatol Venereol 2007;134:567-9.CrossRefPubMed
26.
go back to reference Lapins, J, Ye W, O. Emtestam NL. Incidence of cancer among patients with hidradenitis suppurativa. Arch Dermatol 2001;137:730-4.PubMed Lapins, J, Ye W, O. Emtestam NL. Incidence of cancer among patients with hidradenitis suppurativa. Arch Dermatol 2001;137:730-4.PubMed
27.
go back to reference Maalouf E, Faye O, Poli F, Cosnes A, Revuz J. Fatal epidermoid carcinoma in hidradenitis suppurativa following treatment with infliximab. Ann Dermatol Venereol 2006;133:473-4.CrossRefPubMed Maalouf E, Faye O, Poli F, Cosnes A, Revuz J. Fatal epidermoid carcinoma in hidradenitis suppurativa following treatment with infliximab. Ann Dermatol Venereol 2006;133:473-4.CrossRefPubMed
28.
go back to reference Deckers IE, Van der Zee HH, Prens EP. Severe fatigue based on anaemia in patients with hidradenitis suppurativa: report of two cases and a review of the literature. J Eur Acad Dermatol Venereol 2015;Epub Sept 3. doi:10.1111/jdv.12680.PubMed Deckers IE, Van der Zee HH, Prens EP. Severe fatigue based on anaemia in patients with hidradenitis suppurativa: report of two cases and a review of the literature. J Eur Acad Dermatol Venereol 2015;Epub Sept 3. doi:10.1111/jdv.12680.PubMed
29.
go back to reference Boer J, Jemec GB. Resorcinol peels as a possible self-treatment of painful nodules in hidradenitis suppurativa. Clin Exp Dermatol 2010;35:36-40.CrossRefPubMed Boer J, Jemec GB. Resorcinol peels as a possible self-treatment of painful nodules in hidradenitis suppurativa. Clin Exp Dermatol 2010;35:36-40.CrossRefPubMed
30.
go back to reference Jemec GB, Wendelboe P. Topical clindamycin versus systemic tetracycline in the treatment of hidradenitis suppurativa. J Am Acad Dermatol 1998;39:971-4.CrossRefPubMed Jemec GB, Wendelboe P. Topical clindamycin versus systemic tetracycline in the treatment of hidradenitis suppurativa. J Am Acad Dermatol 1998;39:971-4.CrossRefPubMed
31.
go back to reference Clemmensen OJ. Topical treatment of hidradenitis suppurativa with clindamycin. Int J Dermatol 1983;22:325-8.CrossRefPubMed Clemmensen OJ. Topical treatment of hidradenitis suppurativa with clindamycin. Int J Dermatol 1983;22:325-8.CrossRefPubMed
32.
go back to reference Sapadin AN, Fleischmajer R. Tetracyclines: nonantibiotic properties and their clinical implications. J Am Acad Dermatol 2006;54:258-65.CrossRefPubMed Sapadin AN, Fleischmajer R. Tetracyclines: nonantibiotic properties and their clinical implications. J Am Acad Dermatol 2006;54:258-65.CrossRefPubMed
33.
go back to reference Altenburg J, De Graaff CS, Van der Werf TS, Boersma WG. Immunomodulatory effects of macrolide antibiotics; biological mechanisms. Respiration 2011;81:67-74.CrossRefPubMed Altenburg J, De Graaff CS, Van der Werf TS, Boersma WG. Immunomodulatory effects of macrolide antibiotics; biological mechanisms. Respiration 2011;81:67-74.CrossRefPubMed
34.
go back to reference Van der Zee H, Boer J, Prens E, Jemec GBE. The effect of combined treatment with oral clindamycin and oral rifampicin in patients with hidradenitis suppurativa. Dermatology 2009;219:143-7.CrossRefPubMed Van der Zee H, Boer J, Prens E, Jemec GBE. The effect of combined treatment with oral clindamycin and oral rifampicin in patients with hidradenitis suppurativa. Dermatology 2009;219:143-7.CrossRefPubMed
35.
go back to reference Gener G, Canoui-Poitrine F, Revuz JE, Faye O, Poli F, Gabison G, et al. Combination therapy with clindamycin and rifampicin for hidradenitis suppurativa: a series of 116 consecutive patients. Dermatol 2009;219:148-54.CrossRef Gener G, Canoui-Poitrine F, Revuz JE, Faye O, Poli F, Gabison G, et al. Combination therapy with clindamycin and rifampicin for hidradenitis suppurativa: a series of 116 consecutive patients. Dermatol 2009;219:148-54.CrossRef
36.
go back to reference Nazary M1, Van der Zee HH, Prens EP, Folkerts G, Boer. Pathogenesis and pharmacotherapy of hidradenitis suppurativa. J Eur J Pharmacol 2011;15:1-8.CrossRef Nazary M1, Van der Zee HH, Prens EP, Folkerts G, Boer. Pathogenesis and pharmacotherapy of hidradenitis suppurativa. J Eur J Pharmacol 2011;15:1-8.CrossRef
37.
go back to reference Nederlandse Vereniging voor Dermatologie en Venereologie (NVDV). Richtlijn: Acneïforme dermatosen; 2013. Beschikbaar op: www.huidarts.info. Nederlandse Vereniging voor Dermatologie en Venereologie (NVDV). Richtlijn: Acneïforme dermatosen; 2013. Beschikbaar op: www.​huidarts.​info.
38.
go back to reference Van Rappard DC1, Limpens J, Mekkes JR. The off-label treatment of severe hidradenitis suppurativa with TNF-a inhibitors: a systematic review. J Dermatolog Treat 2013;24:392-404.CrossRefPubMed Van Rappard DC1, Limpens J, Mekkes JR. The off-label treatment of severe hidradenitis suppurativa with TNF-a inhibitors: a systematic review. J Dermatolog Treat 2013;24:392-404.CrossRefPubMed
39.
go back to reference Grant A, Gonzalez T, Montgomery MO, Cardenas V, Kerdel FA. Infliximab therapy for patients with moderate to severe hidradenitis suppurativa: a randomized, double-blind, placebo-controlled crossover trial. J Am Acad Dermatol 2010;62:205-17.CrossRefPubMed Grant A, Gonzalez T, Montgomery MO, Cardenas V, Kerdel FA. Infliximab therapy for patients with moderate to severe hidradenitis suppurativa: a randomized, double-blind, placebo-controlled crossover trial. J Am Acad Dermatol 2010;62:205-17.CrossRefPubMed
40.
go back to reference Adams DR, Yankura JA, Fogelberg AC, Anderson BE. Treatment of hidradenitis suppurativa with etanercept injection. Arch Dermatol 2010;146:501-4.PubMed Adams DR, Yankura JA, Fogelberg AC, Anderson BE. Treatment of hidradenitis suppurativa with etanercept injection. Arch Dermatol 2010;146:501-4.PubMed
41.
go back to reference Miller I, Lynggaard CD, Lophaven S, Zachariae C, Dufour DN, Jemec GB. A double blind placebo controlled randomised trial of adalimumab in the treatment of hidradenitis suppurativa. Brit J Dermatol 2011;165:391-8.CrossRef Miller I, Lynggaard CD, Lophaven S, Zachariae C, Dufour DN, Jemec GB. A double blind placebo controlled randomised trial of adalimumab in the treatment of hidradenitis suppurativa. Brit J Dermatol 2011;165:391-8.CrossRef
42.
go back to reference Kimball A, Jemec G, Okun M, Gu Y. Efficacy and safety of adalimumab in treatment of moderate to severe hidradenitis suppurativa: results from the placebo-controlled portion of a phase II, randomized, double-blind study. J Am Acad Dermatol 2011;64:AB155.CrossRef Kimball A, Jemec G, Okun M, Gu Y. Efficacy and safety of adalimumab in treatment of moderate to severe hidradenitis suppurativa: results from the placebo-controlled portion of a phase II, randomized, double-blind study. J Am Acad Dermatol 2011;64:AB155.CrossRef
43.
go back to reference Ellis LZ. Hidradenitis suppurativa: surgical and other management techniques. Dermatol Surg 2012;38:517-36.CrossRefPubMed Ellis LZ. Hidradenitis suppurativa: surgical and other management techniques. Dermatol Surg 2012;38:517-36.CrossRefPubMed
44.
go back to reference Shah, N. Hidradenitis suppurativa: a treatment challenge. Am Fam Physician 2005;72:1547-52.PubMed Shah, N. Hidradenitis suppurativa: a treatment challenge. Am Fam Physician 2005;72:1547-52.PubMed
45.
go back to reference Ritz JP, Runkel N, Haier J, Buhr HJ. Extent of surgery and recurrence rate of hidradenitis suppurativa. Int J Colorectal Dis 1998;13:164-8.CrossRefPubMed Ritz JP, Runkel N, Haier J, Buhr HJ. Extent of surgery and recurrence rate of hidradenitis suppurativa. Int J Colorectal Dis 1998;13:164-8.CrossRefPubMed
46.
go back to reference Buimer MG, Ankersmit MF, Wobbes T, Klinkenbijl JH. Surgical treatment of HS with gentamycin sulphate: a prospective randomised study. Dermatol Surg 2008;34:224-7.CrossRefPubMed Buimer MG, Ankersmit MF, Wobbes T, Klinkenbijl JH. Surgical treatment of HS with gentamycin sulphate: a prospective randomised study. Dermatol Surg 2008;34:224-7.CrossRefPubMed
47.
go back to reference Danby FW. Commentary: unroo?ng for hidradenitis suppurativa, why and how. J Am Acad Dermatol 2010;63:481.CrossRefPubMed Danby FW. Commentary: unroo?ng for hidradenitis suppurativa, why and how. J Am Acad Dermatol 2010;63:481.CrossRefPubMed
48.
go back to reference Hazen PG, Hazen BP. Hidradenitis suppurativa: successful treatment using carbon dioxide laser excision and marsupialization. Dermatol Surg 2010;36:208-13.CrossRefPubMed Hazen PG, Hazen BP. Hidradenitis suppurativa: successful treatment using carbon dioxide laser excision and marsupialization. Dermatol Surg 2010;36:208-13.CrossRefPubMed
49.
go back to reference Van der Zee HH, Prens EP, Boer J. Deroofing: a tissue-saving surgical technique for the treatment of mild to moderate hidradenitis suppurativa lesions. J Am Acad Dermatol 2010;63:475-80.CrossRefPubMed Van der Zee HH, Prens EP, Boer J. Deroofing: a tissue-saving surgical technique for the treatment of mild to moderate hidradenitis suppurativa lesions. J Am Acad Dermatol 2010;63:475-80.CrossRefPubMed
50.
go back to reference Van Rappard DC, Mooij JE, Mekkes JR. Mild to moderate hidradenitis suppurativa treated with local excision and primary closure. J Eur Acad Dermatol Venereol 2012;26:898-902.CrossRefPubMed Van Rappard DC, Mooij JE, Mekkes JR. Mild to moderate hidradenitis suppurativa treated with local excision and primary closure. J Eur Acad Dermatol Venereol 2012;26:898-902.CrossRefPubMed
51.
go back to reference Ather S, Chan DS, Leaper DJ, Harding KG. Surgical treatment of hidradenitis suppurativa: case series and review of the literature. Int Wound J 2006;3:159-69.CrossRefPubMed Ather S, Chan DS, Leaper DJ, Harding KG. Surgical treatment of hidradenitis suppurativa: case series and review of the literature. Int Wound J 2006;3:159-69.CrossRefPubMed
53.
go back to reference Mooij JE, Van ’t Oost L, Leenarts MF, Mekkes JR. Behandelopties bij ernstige hidradenitis suppurativa. Ned Tijdschr Geneeskd 2011;155:A1912.PubMed Mooij JE, Van ’t Oost L, Leenarts MF, Mekkes JR. Behandelopties bij ernstige hidradenitis suppurativa. Ned Tijdschr Geneeskd 2011;155:A1912.PubMed
54.
go back to reference Wielink G, Koning S, Oosterhout RM, Wetzels R, Nijman FC, Draijer LW. NHG-Standaard Bacteriële huidinfecties (Eerste herziening). Huisarts Wet 2007;50:426-44. Wielink G, Koning S, Oosterhout RM, Wetzels R, Nijman FC, Draijer LW. NHG-Standaard Bacteriële huidinfecties (Eerste herziening). Huisarts Wet 2007;50:426-44.
55.
go back to reference Zorginstituut Nederland. Middelen bij inflammatoire dermatosen. Farmacotherapeutisch Kompas;2014 (geraadpleegd op 4-12-2014). www.fk.cvz.nl. Zorginstituut Nederland. Middelen bij inflammatoire dermatosen. Farmacotherapeutisch Kompas;2014 (geraadpleegd op 4-12-2014). www.​fk.​cvz.​nl.
Metagegevens
Titel
Een invaliderende ontstekingsziekte van de huid
Auteurs
Ouliana Kouznetsova
dr. Hessel van der Zee
dr. Wim van der Meijden
Publicatiedatum
01-05-2016
Uitgeverij
Bohn Stafleu van Loghum
Gepubliceerd in
Huisarts en wetenschap / Uitgave 5/2016
Print ISSN: 0018-7070
Elektronisch ISSN: 1876-5912
DOI
https://doi.org/10.1007/s12445-016-0126-9

Andere artikelen Uitgave 5/2016

Huisarts en wetenschap 5/2016 Naar de uitgave

Praktische epidemiologie

De ROC-curve